Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beer A is a specific brand or product name for beer, an alcoholic beverage produced by the fermentation of cereal grains—primarily barley and/or wheat—using yeast, hops, and water. The primary active ingredient in beer is ethanol (ethyl alcohol), which acts as a central nervous system depressant. Ethanol exerts its effects mainly by enhancing the activity of γ-Aminobutyric acid (GABA) at GABA~A~ receptors in the brain, leading to sedation and anxiolysis. It also modulates other neurotransmitter systems including glutamate, glycine, acetylcholine, serotonin, dopamine, and endogenous opioids[7]. Beer may contain various phenolic compounds from its ingredients (e.g., hops and malted barley), trace nutrients such as B vitamins and minerals[8], but its pharmacological action is dominated by ethanol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beer A.